Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.
about
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patchInfluenza vaccines: a moving interdisciplinary field.Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.
P2860
Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@ast
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@en
type
label
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@ast
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@en
prefLabel
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@ast
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@en
P2093
P2860
P356
P1476
Nonclinical safety evaluation ...... of a nasal influenza vaccine.
@en
P2093
Christian Moser
Ian C Metcalfe
Jean-François Viret
Reinhard Glück
Rinaldo Zurbriggen
P2860
P304
P356
10.1586/14760584.2.2.295
P577
2003-04-01T00:00:00Z